Table 4.
Comparison of AZD7594 versus placebo AUC0–24 plasma cortisol ratios after single day (Day 1) and repeated once-daily dosing for 12 days (Days 5–16)
| Treatment | N | n | Geometric LS mean | 95% CI | Pairwise comparison with placebo | ||
|---|---|---|---|---|---|---|---|
| Ratio (%) |
95% CI | ||||||
| Day 1/Day −1 | Placebo | 6 | 0.9020 | 0.7960; 1.022 | |||
| AZD7594 200 µg | 7 | 7 | 0.9290 | 0.8282; 1.042 | 102.99 | 86.88; 122.09 | |
| AZD7594 400 µg | 7 | 7 | 0.9554 | 0.8518; 1.072 | 105.92 | 89.40; 125.49 | |
| AZD7594 1600 µg | 7 | 7 | 0.9004 | 0.8024; 1.010 | 99.82 | 84.12; 118.46 | |
| Day 16/Day −1 | Placebo | 6 | 0.9627 | 0.8484; 1.092 | |||
| AZD7594 200 µg | 7 | 7 | 0.8839 | 0.7871; 0.9927 | 91.82 | 77.32; 109.04 | |
| AZD7594 400 µg | 7 | 7 | 0.8610 | 0.7667; 0.9668 | 89.44 | 75.35; 106.16 | |
| AZD7594 1600 µg | 7 | 7 | 0.7256 | 0.6458; 0.8153 | 75.38 | 63.40; 89.61 | |
Abbreviations: CI, confidence interval; LS, least squares; N, number in the pharmacokinetic analysis set; n, all subjects included in the statistical comparison analysis.